TY - JOUR
T1 - Expanding Access to Medications for Opioid Use Disorder
T2 - Program and Policy Approaches from Outside the Veterans Health Administration
AU - Priest, Kelsey C.
AU - McCarty, Dennis
AU - Lovejoy, Travis I.
N1 - Publisher Copyright:
© 2020, Society of General Internal Medicine.
PY - 2020/12
Y1 - 2020/12
N2 - To mitigate morbidity and mortality of the drug-related overdose crisis, the Veterans Health Administration (VHA) can increase access to treatments that save lives—medications for opioid use disorder (MOUD). Despite an increasing need, MOUD continues to be underutilized due to multifaceted barriers that exist within broader macro- and microenvironments. To promote MOUD utilization, policymakers and healthcare leaders should (1) identify and implement person-centered MOUD delivery systems (e.g., the Medication First Model, community-informed design); (2) recognize and address MOUD delivery gaps (e.g., the Best-Practice in Oral Opioid Agonist Collaborative); (3) broaden the definition of the MOUD delivery system (e.g., access to MOUD in non-clinical settings); and (4) expand MOUD options (e.g., injectable opioid agonist therapy). Increasing access to MOUD is not a singular fix to the overdose-related crisis. It is, however, a possible first step to mitigate harm, and save lives.
AB - To mitigate morbidity and mortality of the drug-related overdose crisis, the Veterans Health Administration (VHA) can increase access to treatments that save lives—medications for opioid use disorder (MOUD). Despite an increasing need, MOUD continues to be underutilized due to multifaceted barriers that exist within broader macro- and microenvironments. To promote MOUD utilization, policymakers and healthcare leaders should (1) identify and implement person-centered MOUD delivery systems (e.g., the Medication First Model, community-informed design); (2) recognize and address MOUD delivery gaps (e.g., the Best-Practice in Oral Opioid Agonist Collaborative); (3) broaden the definition of the MOUD delivery system (e.g., access to MOUD in non-clinical settings); and (4) expand MOUD options (e.g., injectable opioid agonist therapy). Increasing access to MOUD is not a singular fix to the overdose-related crisis. It is, however, a possible first step to mitigate harm, and save lives.
UR - http://www.scopus.com/inward/record.url?scp=85094966554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094966554&partnerID=8YFLogxK
U2 - 10.1007/s11606-020-06266-3
DO - 10.1007/s11606-020-06266-3
M3 - Editorial
C2 - 33145685
AN - SCOPUS:85094966554
SN - 0884-8734
VL - 35
SP - 886
EP - 890
JO - Journal of general internal medicine
JF - Journal of general internal medicine
ER -